SCHEMBL1577589

SCHEMBL1577589

Nc1ccc(OCc2ccc(C3CCN(C(=O)O)CC3)cn2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPC6 Q9Y210 4/20 0.44
MRGPRX4 Q96LA9 1/20 0.40
PRMT5 O14744 2/20 0.40
HRH3 Q9Y5N1 1/20 0.39
CYSLTR2 Q9NS75 2/20 0.39
CYSLTR1 Q9Y271 2/20 0.39
ALDH1A1 P00352 2/20 0.38
GAA P10253 2/20 0.38
MAPT P10636 2/20 0.38
HTT P42858 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
RAB9A P51151 1/20 0.38
QDPR P09417 1/20 0.36
EGLN1 Q9GZT9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1577998 0.88 CA12 (0.47) TRPC6HRH3
SCHEMBL1577335 0.87 PRMT5 (0.42) TRPC6MRGPRX4PRMT5MAPTSMN1; SMN2
SCHEMBL1577527 0.86 GPR119 (0.48) TRPC6PRMT5
SCHEMBL1577844 0.86 LMNA (0.44) ALDH1A1MAPTSMN1; SMN2CYP1A2CYP2D6
SCHEMBL1577840 0.86 LMNA (0.44) ALDH1A1MAPTSMN1; SMN2CYP1A2CYP2D6
SCHEMBL1577678 0.85 DDB1 (0.52) PRMT5ALDH1A1HTT
SCHEMBL1577565 0.85 MAPT (0.47) PRMT5MAPTL3MBTL1SMN1; SMN2CYP1A2
SCHEMBL1952795 0.83 PRMT5 (0.42) TRPC6MRGPRX4PRMT5HRH3CYSLTR2
SCHEMBL1577824 0.83 NPY2R (0.42) TRPC6PRMT5HRH3ALDH1A1MAPT
SCHEMBL1577838 0.83 NPC1 (0.44) TRPC6PRMT5HRH3MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140018537-A1 GPR119 AGONIST NIPPON CHEMIPHAR CO., LTD. (JP) 2014-01-16 US disclosed
US-8536176-B2 GPR119 agonist NIPPON CHEMIPHAR CO., LTD. (JP) 2013-09-17 US disclosed
US-20110137032-A1 GPR119 AGONIST NIPPON CHEMIPHAR CO., LTD. (JP) 2011-06-09 US disclosed
EP-2311822-A1 GPR119 AGONIST Nippon Chemiphar Co., Ltd. (JP) 2011-04-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140018537-A1 GPR119 AGONIST GPR119, GPR27, GPR52 TRPC6 485/4885MRGPRX4 333/4885PRMT5 839/4885
US-20110137032-A1 GPR119 AGONIST GPR119, GPR27, GPR52 TRPC6 485/4885MRGPRX4 333/4885PRMT5 839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.